Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 7/20 | 0.33 |
| ▸ | HNF4A | P41235 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223569 | 1.00 | GAA (0.36) | GAAMAPK1MAPTDYRK1ADYRK1B | |
| SCHEMBL5226377 | 0.81 | GAA (0.40) | GAAMAPK1MAPTDYRK1ADYRK1B | |
| SCHEMBL5226382 | 0.78 | MAPK1 (0.40) | GAAMAPK1MAPTDYRK1ADYRK1B | |
| SCHEMBL5228583 | 0.77 | ALOX5 (0.44) | GAAMAPTDYRK1ADYRK1BMTNR1A | |
| SCHEMBL172896 | 0.70 | MAPT (0.48) | GAAMAPK1MAPT | |
| SCHEMBL5256443 | 0.68 | MTNR1A (0.42) | MTNR1ADPP4 | |
| SCHEMBL5225798 | 0.68 | MTNR1A (0.40) | MTNR1ANQO2 | |
| SCHEMBL19313470 | 0.68 | MTNR1A (0.49) | MTNR1ADPP4 | |
| SCHEMBL22135640 | 0.67 | MTNR1A (0.48) | MTNR1ADPP4 | |
| SCHEMBL31028101 | 0.65 | PIK3CA (0.38) | GAAMAPK1MAPTDYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998471-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | GAA 3348/4885MAPK1 3126/4885MAPT 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.